Systematic review and bivariate/HSROC random-effect meta-analysis of immunochemical and guaiac-based fecal occult blood tests for colorectal cancer screening

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 9, 2014, Pages 978-989

  Launois, Robert ^a   Le Moine, Jean Gabriel ^a   Uzzan, Bernard ^b   Fiestas Navarrete, Lucia I ^a   Benamouzig, Robert ^b  

^a Evaluation Network for Health Economics (REES) France   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

accuracy; advanced adenomas; bivariate; colorectal cancer; diagnostic test; HSROC; literature review; meta analysis; QUADAS

Indexed keywords

GUAIAC; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; DIAGNOSTIC TEST ACCURACY STUDY; GOLD STANDARD; GUAIAC BASED FECAL OCCULT BLOOD TEST; HUMAN; IMMUNOCHEMISTRY; IMMUNOLOGICAL FECAL OCCULT BLOOD TEST; META ANALYSIS; OCCULT BLOOD; OCCULT BLOOD TEST; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SENSOR; SYSTEMATIC REVIEW; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; PROCEDURES;

COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; GUAIAC; HUMANS; INDICATORS AND REAGENTS; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY;

EID: 84905396120     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000160     Document Type: Article

References (51)

1. Belot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, Delafosse P, et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 2008; 56:159-175.
2. Jeong KE, Cairns JA. Review of economic evidence in the prevention and early detection of colorectal cancer. Health Econ Rev 2013; 3:20.
3. Nakajima M, Saito H, Soma Y, Sobue T, Tanaka M, Munakata A. Prevention of advanced colorectal cancer by screening using the immunochemical faecal occult blood test: a case-control study. Br J Cancer 2003; 89:23-28.
4. Lee KJ, Inoue M, Otani T, Iwasaki M, Sasazuki S, Tsugane S. Japan Public Health Center-based Prospective Study. Colorectal cancer screening using fecal occult blood test and subsequent risk of colorectal cancer: a prospective cohort study in Japan. Cancer Detect Prev 2007; 31:3-11.
5. Thosani N, Guha S, Singh H. Colonoscopy and colorectal cancer incidence and mortality. Gastroenterol Clin North Am 2013; 42:619-637.
6. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, et al. Longterm colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013; 369:1095-1105.
7. Park DI, Ryu S, Kim YH, Lee SH, Lee CK, Eun CS, Han DS. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010; 105:2017-2025.
8. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
9. Brecht JG, Robra BP. A graphic method of estimating the specificity of screening programmes from incomplete follow-up data. Methods Inf Med 1987; 26:53-58.
10. Soares KV, Burch JA, Duffy S St, John DJ, Smith S, Westwood M, et al. Diagnostic accuracy and cost-effectiveness of faecal occult blood tests used in screening for colorectal cancer: a systematic review. London: Center for Research Dissemination; 2007.
11. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149:638-658.
12. Potvin E, Gosselin C. Test immunochimique de recherche de sang occulte dans les selles. Détermination d'un seuil de positivité pour démarrer les projets de démonstration du PQDCCR. Québec: Institut national d'excellence en santé et en services sociaux (INESSS); 2012.
13. Perez P, Saves M, Picat M-Q, Chene G. Methods in Clinical Research University Diploma: Massive Online Open Course; 2013.
14. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155:529-536.
15. Rutter CM, Gatsonis CA. A hierarchical regression approach to metaanalysis of diagnostic test accuracy evaluations. Stat Med 2001; 20:2865-2884.
16. Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. York: University of York; 2009.
17. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005; 58:982-990.
18. Sutton AJ, Cooper NJ, Goodacre S, Stevenson M. Integration of metaanalysis and economic decision modeling for evaluating diagnostic tests. Med Decis Making 2008; 28:650-667.
19. Cox C. Delta method. In: Armitage P, Colton T, editors. Encyclopedia of biostatistics. New York: Wiley; 1998. pp. 1125-1127.
20. Macaskill P. Empirical Bayes estimates generated in a hierarchical summary ROC analysis agreed closely with those of a full Bayesian analysis. J Clin Epidemiol 2004; 57:925-932.
21. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240:1285-1293.
22. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008; 149:441-450.
23. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occultblood tests for colorectal-cancer screening. N Engl J Med 1996; 334:155-159.
24. Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer 2013; 49:3049-3054.
25. Chen LS, Liao CS, Chang SH, Lai HC, Chen TH. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). J Med Screen 2007; 14:191-199.
26. Chen LS, Yen AM, Chiu SY, Liao CS, Chen HH. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol 2011; 12:551-558.
27. Cheng TI, Wong JM, Hong CF, Cheng SH, Cheng TJ, Shieh MJ, et al. Colorectal cancer screening in asymptomaic adults: comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. J Formos Med Assoc 2002; 101:685-690.
28. Chiang TH, Lee YC, Tu CH, Chiu HM, Wu MS. Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract. CMAJ 2011; 183:1474-1481.
29. Itoh M, Takahashi K, Nishida H, Sakagami K, Okubo T. Estimation of the optimal cut off point in a new immunological faecal occult blood test in a corporate colorectal cancer screening programme. J Med Screen 1996; 3:66-71.
30. Levi Z, Birkenfeld S, Vilkin A, Bar-Chana M, Lifshitz I, Chared M, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer 2011; 2415-2424.
31. Miyoshi H, Ohshiba S, Asada S, Hirata I, Uchida K. Immunological determination of fecal hemoglobin and transferrin levels: a comparison with other fecal occult blood tests. Am J Gastroenterol 1992; 87:67-73.
32. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129:422-428.
33. Nakama H, Fattah A, Zhang B, Uehara Y, Wang C. A comparative study of immunochemical fecal tests for detection of colorectal adenomatous polyps. Hepatogastroenterology 2000; 47:386-389.
34. Nakama H, Kamijo N. Accuracy of immunological fecal occult blood testing for colorectal cancer screening. Prev Med 1994; 23:309-313.
35. Nakama H, Zhang B, Fattah AA, Kamijo N, Zhang X. Characteristics of colorectal cancer that produce positive immunochemical occult blood test results on stool obtained by digital rectal examination. Can J Gastroenterol 2001; 15:227-230.
36. Nakama H, Zhang B, Kamijo N. Sensitivity of immunochemical fecal occult blood test for colorectal flat adenomas. Hepatogastroenterology 2004; 51:1333-1336.
37. Nakama H, Zhang B, Zhang X. Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer 2001; 37:398-401.
38. Niv Y, Lev-El M, Fraser G, Abuksis G, Tamir A. Protective effect of faecal occult blood test screening for colorectal cancer: worse prognosis for screening refusers. Gut 2002; 50:33-37.
39. Oort FA, Terhaar Sive Droste JS, Van Der Hulst RW, Van Heukelem HA, Loffeld RJ, Wesdorp IC, et al. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiacbased faecal occult blood test. Aliment Pharmacol Ther 2010; 31:432-439.
40. Robinson MH, Marks CG, Farrands PA, Thomas WM, Hardcastle JD. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br J Surg 1994; 81:448-451.
41. St John DJ, Young GP, Alexeyeff MA, Deacon MC, Cuthbertson AM, Macrae FA, Penfold JC. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 1993; 104:1661-1668.
42. Sung JJ, Chan FK, Leung WK, Wu JC, Lau JY, Ching J, et al. Screening for colorectal cancer in Chinese: comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Gastroenterology 2003; 124:608-614.
43. Saito H, Soma Y, Koeda J, Wada T, Kawaguchi H, Sobue T, et al. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int J Cancer 1995; 61:465-469.
44. Saito H, Soma Y, Nakajima M, Koeda J, Kawaguchi H, Kakizaki R, et al. A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test. Oncol Rep 2000; 7:815-819.
45. Launoy GD, Bertrand HJ, Berchi C, Talbourdet VY, Guizard AV, Bouvier VM, Caces ER. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general averagerisk population. Int J Cancer 2005; 115:493-496.
46. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, Bossuyt PM. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999; 282:1061-1066.
47. Westwood ME, Whiting PF, Kleijnen J. How does study quality affect the results of a diagnostic meta-analysis? BMC Med Res Methodol 2005; 5:20.
48. Whyte S, Chilcott J, Cooper C, Essat M, Stevens J, Wong R, et al. Re-appraisal of the options for colorectal cancer screening. Report for the NHS Bowel Cancer Screening Programme. Sheffield: School of Health and Related Research (SCHARR); 2011.
49. Nakama H, Zhang B, Abdul Fattah AS, Kamijo N, Fukazawa K. Relationships between a sign of rectal bleeding and the results of an immunochemical occult blood test, and colorectal cancer. Eur J Cancer Prev 2000; 9:325-328.
50. Deeks J, Higgins J, Altman DG. Analysing data and under taking metaanalyses. In: Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions, Cochrane Book Series. Chichester, UK: John Wiley & Sons Ltd; 2008.
51. Schmidt RL, Factor RE. Understanding sources of bias in diagnostic accuracy studies. Arch Pathol Lab Med 2013; 137:558-565.